Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 226915
                    [Title] => Experts debate first-line therapy for heart failure
                    [Summary] => Results of new clinical trials are reinforcing the role of the angiotensin receptor blockers (ARBs) in the treatment of patients with heart failure (HF). 


Previously, the angiotensin converting enzyme inhibitors (ACEi) were considered as first-line drug in HF patients. Now, heart experts are debating if ARBs can also be considered as another first-line drug to be given with ACEi or to replace it altogether in those who cannot tolerate ACEi due to side-effects, which can be as many as 35 percent of HF patients. 


                    [DatePublished] => 2003-11-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

GOTEBORG UNIVERSITY AND SAHLGRENSKA UNIVERSITY HOSPITAL

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 226915
                    [Title] => Experts debate first-line therapy for heart failure
                    [Summary] => Results of new clinical trials are reinforcing the role of the angiotensin receptor blockers (ARBs) in the treatment of patients with heart failure (HF). 


Previously, the angiotensin converting enzyme inhibitors (ACEi) were considered as first-line drug in HF patients. Now, heart experts are debating if ARBs can also be considered as another first-line drug to be given with ACEi or to replace it altogether in those who cannot tolerate ACEi due to side-effects, which can be as many as 35 percent of HF patients. 


                    [DatePublished] => 2003-11-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Experts debate first-line therapy for heart failure

November 6, 2003 - 12:00am

Results of new clinical trials are reinforcing the role of the angiotensin receptor blockers (ARBs) in the treatment of patients with heart failure (HF). Previously, the angiotensin converting enzyme inhibitors...

Science and Environment